The Chief Scientific Officer of Spark Therapeutics, Federico Mingozzi, surveys the hopes and challenges facing the human gene therapy community.
After a distinguished career in academic medicine, including stints at the Children's Hospital of Philadelphia, INSERM and Genethon in France, Federico Mingozzi joined Spark Therapeutics three years ago as chief scientific officer.
Mingozzi aims to build on the company's landmark success with Luxturna, the approved therapy for certain retinal diseases such as the type 2 version of Leber's congenital amaurosis (LCA). In this recent interview with Kevin Davies, Mingozzi discusses his career highlights . . .